Median Technologies Shares Gain Over 5% and Double in Value Over a Year
Median Technologies shows significant progress this Monday, with a share price of €5.13 in mid-afternoon trading, marking a 5.45% increase from last Friday's close. The small cap company, specializing in AI-assisted medical imaging, continues its upward trajectory, having doubled its value over the past twelve months.
A Technical Rebound Bringing the Stock Close to Its Upper Bollinger Band
Median Technologies shares are trading at €5.13, showing a notable rise after closing at €4.865. This movement positions the price in the upper part of its Bollinger Bands, at 69% of the range defined by a lower bound of €4.47 and an upper bound of €5.43. The stock is thus approaching this upper limit, beyond which an overbought situation could materialize. However, the RSI, a momentum indicator, remains moderate at 43, indicating no directional excess at this stage. The price simultaneously crosses its 20-day (€4.95) and 50-day (€4.84) moving averages, signals that indicate a short-term resurgence in strength. The 200-day moving average, significantly lower at €3.29, confirms the long-term bullish trend that has been established over the past year. The nearest support is located at €4.55, while the major identified resistance is at €6.59, nearly 28% above the current level.
An Annual Performance of 100% Driven by Marked Volatility
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Median Technologies' progression over the past year reaches 100.3%, a remarkable dynamic for this digital health stock listed on Euronext Growth. Over three months, the gain is set at 14%, and the weekly performance is at +3.64%. However, this journey is accompanied by high volatility: the one-month volatility indicator stands at 32.52%, indicating significant price variations from one session to another. A negative beta of -0.11 indicates a low correlation with the overall market, characteristic of a niche technological value moving according to its own catalysts. Meanwhile, the CAC 40 is up marginally by 0.03% at 8,159.98 points during the session, while the DAX advances by 0.59%. The European environment thus appears relatively calm, confirming that the pronounced rise in the stock is due to company-specific factors rather than a generalized sector movement.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux / imagerie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 11,8 millions d'euros
Quarterly revenue: 11,8 millions d'euros
Guidance from the release
The Company expects continued growth of its profitable iCRO business, supported by record backlog levels and favorable commercial momentum, but primary focus remains execution of eyonis® LCS commercialization with inherent execution risk.
Risks mentioned
Risques de fluctuations de demande dans l'industrie biopharmaceutique.
Réglementations changeantes pouvant impacter la commercialization.
Concurrence accrue sur le marché des dispositifs médicaux.
Opportunities identified
Lancement commercial d'eyonis® LCS aux États-Unis.
Partenariat stratégique avec Tempus AI en cours.
Croissance continue de l'activité iCRO avec des niveaux de carnet de commandes record.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.